Skip to content

Epidemiology of Gonococcal Arthritis (EpGAr)

Epidemiology of Gonococcal Arthritis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06897943
Acronym
EpGAr
Enrollment
11
Registered
2025-03-27
Start date
2024-12-01
Completion date
2025-04-30
Last updated
2025-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis, Infectious, Gonococcal (GC) Infection

Keywords

gonococcal arthritis

Brief summary

The aim of this retrospective observational study was to describe the epidemiology of Neisseria gonorrhoeae septic arthritis over the last 10 years at Brest and Rennes university hospitals. The main question is whether there are any risk factors based on the epidemiological and clinical data on these cases. The second objective is to characterize the gonococcal strains isolated in order to determine whether there is a common clone, a virulence factor or specific resistance genes.

Interventions

None listed

Sponsors

University Hospital, Brest
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients with a Neisseria gonorrhoeae-positive joint sample (from an enrichment vial or a native sample) between 2014 and 2024.

Exclusion criteria

* Patients with Neisseria gonorrhoeae-negative joint sample (from enrichment vial or native sample). * Patients who have expressed opposition to inclusion in the study. * Patients under legal protection (guardianship, curatorship, etc.).

Design outcomes

Primary

MeasureTime frameDescription
Rate of CRP (C-reactive protein)10 yearsin mg/L
Surgery10 yearsyes or not
Evolution10 yearsrecovery or relapse
Rate of neutrophils10 yearsproportion of neutrophils in %.
Age10 yearsyears
Date of sampling10 yearsDD/MM/YYYY
Type of sample10 yearsjoint fluid or joint fluid on blood culture bottle
Rate of white blood cells10 yearsquantification of white blood cells /mm3
Sexually transmitted infection10 yearsassociated or not, if associated, name of STI and localization
Men who have sex with men10 yearsyes or no
HIV pre-exposure prophylaxis (PreP)10 yearsyes or no
Comorbidities10 yearsany history mentioned in the medical file, such as fracture, illness, treatment, chronic alcoholism, cancer, diabetes, etc.
Imaging10 yearsmedical conclusion of the ultrasound or radiology performed
Blood cultures (peripheral blood)10 yearspositive or negative
Time to diagnosis10 yearsin days (between onset of symptoms and antibiotics)
Treatments implemented10 yearsname of the probabilistic treatment (antibiotic) and after identification or antibiogram
Antibiotic sensitivity profile10 yearsSusceptibility or resistance according to SIR methodology and, if achieved: minimum inhibitory concentrations of antibiotics tested on the strain in mg/L

Secondary

MeasureTime frameDescription
Molecular typing: virulence factors10 yearsperformed on strains sent to the Centre National de Référence des IST - APHP
Molecular typing: resistance genes10 yearsperformed on strains sent to the Centre National de Référence des IST - APHP
Molecular typing: clone10 yearsperformed on strains sent to the Centre National de Référence des IST - APHP

Countries

France

Contacts

Primary ContactGeneviève HERY-ARNAUD
genevieve.hery-arnaud@univ-brest.fr0298145107
Backup ContactValentin LEMOINE
valentin.lemoine@chu-brest.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026